Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 6 years of Total Non-Current Liabilities data on file, last reported at $45.7 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $45.7 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $45.7 million (changed N/A YoY), and the FY2025 annual result was $48.2 million, up 11.49% from the prior year.
• Total Non-Current Liabilities retreated to $45.7 million in Q1 2026 per XENE's latest filing, from $48.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $48.2 million in Q4 2025 and troughed at $43.2 million in Q4 2024.
• A 3-year average of $45.6 million and a median of $45.5 million in 2025 frame the typical range for Total Non-Current Liabilities.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 11.49% in 2025 and fell as far as 11.49% in 2025.
• A 3-year view of Total Non-Current Liabilities shows it stood at $43.2 million in 2024, then increased by 11.49% to $48.2 million in 2025, then fell by 5.1% to $45.7 million in 2026.
• Business Quant data shows XENE's Total Non-Current Liabilities at $45.7 million in Q1 2026, $48.2 million in Q4 2025, and $45.2 million in Q3 2025.